Bicycle Therapeutics (BCYC) Income from Continuing Operations (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Income from Continuing Operations came in at 50343000.0 in Q2 2026, up 36.24% YoY from 36952803.86 in Q2 2025, and up 17.27% on a QoQ basis from 60853000.0 in Q1 2026.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of Income from Continuing Operations data on file, last reported at 50343000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 36.24% year-over-year to 50343000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 142244000.0 (up 42.68% YoY) and the FY2025 annual result came in at 170754000.0, up 2.32% from the prior year.
- Income from Continuing Operations rose to 50343000.0 in Q2 2026, from 60853000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 28052000.0 in Q4 2025 to a low of 78952000.0 in Q2 2025.
- A 5-year average of 42088888.89 and a median of 46084500.0 in 2023 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 148.66% in 2025, down 129.1% in 2025.
- Tracing BCYC's Income from Continuing Operations over 5 years: stood at 36988000.0 in 2022, then sank by 34.01% to 49566000.0 in 2023, then retreated by 16.31% to 57650000.0 in 2024, then jumped by 148.66% to 28052000.0 in 2025, then tumbled by 279.46% to 50343000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 50343000.0 (Q2 2026), 60853000.0 (Q1 2026), and 28052000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bicycle Therapeutics | 298.42 Mn | 298.42 Mn | - | -50.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.34 Mn |
| Mar 31, 2026 | -60.85 Mn |
| Dec 31, 2025 | 28.05 Mn |
| Sep 30, 2025 | -59.10 Mn |
| Jun 30, 2025 | -78.95 Mn |
| Mar 31, 2025 | -60.74 Mn |
| Dec 31, 2024 | -57.65 Mn |
| Sep 30, 2024 | -50.80 Mn |
| Jun 30, 2024 | -39.81 Mn |
| Mar 31, 2024 | -26.51 Mn |
| Dec 31, 2023 | -49.57 Mn |
| Sep 30, 2023 | -49.93 Mn |
| Jun 30, 2023 | -42.60 Mn |
| Mar 31, 2023 | -39.06 Mn |
| Dec 31, 2022 | -36.99 Mn |
| Sep 30, 2022 | -28.35 Mn |
| Jun 30, 2022 | -26.83 Mn |
| Mar 31, 2022 | -27.56 Mn |
| Dec 31, 2021 | -19.06 Mn |
| Sep 30, 2021 | -14.68 Mn |